Table 2. Uni- and multivariable analyses to identify predictors of major pathologic response in the training cohort.
| Variables | Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | ||
| Gender (male vs. female) | 0.784 | 0.460–1.337 | 0.372 | – | – | – | |
| Age (≥65 vs. <65 years) | 0.800 | 0.431–1.486 | 0.480 | – | – | – | |
| Primary tumor | |||||||
| T category (T3-4 vs. T1-2) | 0.721 | 0.352–1.477 | 0.372 | – | – | – | |
| N category (N1-2 vs. N0) | 1.045 | 0.603–1.811 | 0.875 | – | – | – | |
| Site (right vs. left) | 0.740 | 0.379–1.443 | 0.376 | – | – | – | |
| Liver metastases | |||||||
| DFI (<12 vs. ≥12 months) | 1.889 | 1.083–3.292 | 0.025 | 1.908 | 1.026–3.547 | 0.041 | |
| Tumor size (<3 vs. ≥3 cm) | 4.739 | 2.747–8.197 | <0.001 | 5.076 | 2.849–9.010 | <0.001 | |
| Tumor number (single vs. multiple) | 1.984 | 1.070–3.676 | 0.030 | 2.625 | 1.302–5.291 | 0.007 | |
| Distribution (unilobar vs. bilobar) | 1.447 | 0.867–2.415 | 0.157 | – | – | – | |
| RAS status (wild type vs. mutated type) | 1.739 | 1.029–2.932 | 0.038 | 2.217 | 1.227–4.000 | 0.008 | |
| Chemotherapy cycles (≤4 vs. >4) | 1.563 | 0.928–2.632 | 0.093 | – | – | – | |
| Bevacizumab (yes vs. no) | 1.162 | 0.672–2.012 | 0.591 | – | – | – | |
| CEA (≤50 vs. >50 ng/mL) | 2.597 | 1.406–4.808 | 0.002 | 1.684 | 0.833–3.401 | 0.147 | |
| Tumor radiographic assessment (decrease vs. increase) | 1.580 | 0.820–3.040 | 0.172 | – | – | – | |
CEA, carcinoembryonic antigen; DFI, disease-free interval; OR, odds ratio.